Cisplatin is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and acquired resistance limit its application in many types of cancer including prostate. We report a unique strategy to deliver cisplatin to prostate cancer cells by constructing Pt ( DNA cross-link ͉ metals in medicine ͉ PSMA ͉ controlled release
P
rostate cancer (PCa) is the most common form of cancer and the second leading cause of death after lung cancer among men in the United States (1) . In 2008, there are estimated to be 186,320 domestic new cases and 28,660 deaths by PCa (1) . A strategy for treating prostate and other types of cancer involves targeting antigens specific for the tumor of interest. Identification of several prostate antigens offers possible candidates for targeted therapy. The most appealing antigen is the prostatespecific membrane antigen (PSMA) (2, 3) . PSMA is abundantly expressed in prostate cancer, its metastatic form, and the hormone-refractory form (4, 5) and the neovascularture of many non-prostate solid tumors (6) . PSMA is a type II membrane protein with folate hydrolase activity (7, 8) .
The ability of cis-diamminedichloroplatinum(II), cisplatin (9, 10) , to inhibit the growth of cancer cells by interfering with transcription and other DNA-mediated cellular functions has been elucidated over the past 30 years. Cisplatin is highly effective against several forms of cancer, most notably testicular tumors, and it is also commonly used to treat breast, ovarian, bladder, lung, and head and neck cancer. Prostate cancer is resistant to cisplatin chemotherapy due to poor targeting and the development of resistance (11) . To overcome the latter, the cisplatin dosage can be elevated, but not without serious side effects. Because cisplatin is the most potent member of the Pt anticancer drug family, its potential use in prostate cancer is attractive. We therefore devised a strategy for cisplatin therapy in prostate cancer based on mechanisms that target critical molecular pathways of prostate tumors and that employ platinum chemistry and delivery vehicles for such targeting.
Targeted controlled release drug delivery systems have the potential to induce dramatic and durable clinical responses. Designing drug delivery systems that target specific sites with controlled release of the drug over a period is challenging (12) (13) (14) . Controlled release polymeric nanoparticles (NPs) are a powerful technology in this regard (15) (16) (17) (18) . With surface engineering, it is possible to introduce ligands, such as peptides, antibodies, or nucleic acid aptamers, that can target NPs to a cancer cell of interest. Encapsulation of a drug within the interior of the particle protects it from the external environment, increasing blood circulation time of the active dose before reaching its target. A platinum complex encapsulated within nanoparticles administered to a patient will be protected from body fluids before reaching the target cell and its nuclear DNA, and the body will also be isolated from undesired chemical consequences of the drug.
NPs based on biodegradable, biocompatible, and FDAapproved components are of interest because their use facilitates their future transition into clinical trials. NPs derived from poly(D,L-lactic-co-glycolic acid) (PLGA) as the controlled release polymer system are an excellent choice since their safety in clinic is well established (13) . Poly(ethylene glycol) (PEG)-functionalized PLGA NPs are especially desirable because pegylated polymeric NPs have significantly reduced systemic clearance compared with similar particles without PEG (19, 20) . A number of FDA approved drugs in clinical practice use PEG for improved pharmaceutical properties (21) .
In this study, we applied a Pt(IV)-prodrug approach previously employed in our laboratory (22) (23) (24) (25) to deliver cisplatin, using PSMA targeted pegylated PLGA NPs as the vehicle (26) . Encapsulation of cisplatin into polymeric NPs is a challenge because of its physico-chemical properties (27, 28) . Cisplatin is insoluble in organic solvents, and its partial solubility in water makes it difficult to obtain cisplatin-encapsulated-PLGA sustained-release systems that maintain adequate concentrations for long time periods (28) . A recent effort to prepare such a construct by the double emulsion method resulted in large particles, which tend to sequester in the liver and spleen (29) , with encapsulated cisplatin exhibiting lower cytotoxicity than that of the free drug (30) . Particles Ͼ200 nm are generally ineffective in vivo. In another report, the in vitro anticancer activity of cisplatin-encapsulated PLGA-mPEG nanoparticles was investigated against prostate cancer LNCaP cells, but the nanoparticles loaded with cisplatin showed comparable or lower activity compared with that of free cisplatin (31) . The prodrug approach, where cisplatin is released from a Pt(IV) precursor, overcomes the problems associated with cisplatin encapsulation, and allows a cell targeting moiety to deliver a lethal dose of cisplatin upon intracellular reduction (22) (23) (24) (25) . Because the interior of nanoparticles is more hydrophobic than their surface, we prepared a Pt(IV) compound c,t,c [Pt(NH 3 ) 2 (O 2 CCH 2 CH 2 CH 2 CH 2 CH 3 ) 2 Cl 2 ] (1, Scheme 1) having alkyl chains at the axial positions. Encapsulation of this molecule into pegylated PLGA nanoparticle bioconjugates that bind to the PSMA protein on the surface of prostate cancer cells for targeted delivery of the Pt(IV) prodrug led to release of cisplatin upon intracellular reduction (Scheme 1). Although related constructs were devised many years ago (32) , the choice of the linear hexyl chains in 1 was the result of a systematic study to optimize encapsulation and controlled release from the polymer without compromising either feature. For targeting, we used the A10 2Ј-fluoropyrimidine RNA aptamer, which recognizes the extracellular domain of PSMA (A10 PSMA Apt) (33) to functionalize the surface of our Pt(IV)-encapsulated pegylated PLGA NPs. The results of these experiments are described here.
Results and Discussion
Synthesis and Characterization of 1. The interior of nanoparticles is more hydrophobic than their surface. Initial efforts to obtain the required hydrophobicity included synthesis of a Pt(IV) derivative of cisplatin having with adamantyl groups at the axial positions, but this compound was insoluble in acetonitrile. To obtain a platinum complex with sufficient hydrophobicity for encapsulation in PLGA-b-PEG NPs, we ultimately synthesized
(1) (Scheme 1) (22, 32) . The structure of 1 was confirmed by spectroscopic [supporting information (SI) Fig. S1 ], analytical, and X-ray crystallographic methods. Details of the structure are available in Table S1 and Fig. S2 . Synthesis of Pt(IV)-encapsulated nanoparticles requires that the Pt(IV) host be sufficiently soluble in organic solvents like acetonitrile and DMF. Compound 1 dissolves in acetonitrile (10 mg/ml), making it a suitable candidate for encapsulation.
Development of Pt(IV)-Encapsulated, A10 PSMA Apt Funtionalized NPs
(Pt-NP-Apt). PLGA-COOH and NH 2 -PEG 3400 -COOH polymers were used to prepare a PLGA-b-PEG copolymer with terminal carboxylic acid groups (PLGA-b-PEG-COOH) (34) . PLGA-COOH was converted to its succinimide by using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), which was then allowed to react with NH 2 -PEG-COOH. We used a nanoprecipitation method (35) to encapsulate 1 within a PLGA-b-PEG block copolymer having a terminal carboxylic acid group (PLGA-b-PEG-COOH) (Fig. 1A) . The properties of the encapsulated nanoparticle were characterized by dynamic light scattering to give the size and polydispersity of each preparation. To optimize the size and loading, a series of encapsulated NPs were prepared, varying the weight percentage of 1 to polymer and by using PLGA of various molecular masses. In this way, we found PLGA of inherent viscosity 0.69 dL/g in hexafluoroisopropanol to afford the most suitable encapsulated NPs.
The loading efficiencies of 1 at various added weightpercentage values of Pt(IV) to polymer are shown in Fig. 1B . The polydispersity of the particles increases with the percentage loading of 1 ( Table 1 ). The size of the particles also increases with percentage loading (Table 1) . For all studies, we used encapsulated particles having a Ϸ6% loading and a size of Ϸ140 nm (Fig. 1C) . We modified the surface of 1-encapsulated NPs with the A10 PSMA Apt. The presence of targeting moieties on the surface of particles allows it to differentially bind and become internalized by PCa cells. The 5Ј amino groups of the aptamer were conjugated to the carboxylate groups of the NPs surface using an amide coupling reagent. Conjugation of the A10 PSMA Apt on the surface of NPs was confirmed by agarose gel electrophoresis (Fig. S3a) .
In Vitro Controlled Release of 1 from Encapsulated NPs. We next studied the controlled release kinetics of the Pt(IV) complex 1 from the NPs, a necessary property for anticancer activity (36) . Doxorubicin covalently linked to PLGA (37) or poly(aspartic acid) (38) displays very little or no activity because the absence of a hydrolyzable linker precluded its release. A more recent study in which doxorubicin was conjugated to PLGA by a hydrolyzable carbamate linkage showed a sustained release drug profile from this nanocell delivery system (39) . The platinum(IV) compound is physically dispersed by encapsulation throughout the hydrophobic core of the PLGA-b-PEG NPs. Typically, except for an initial burst, release from polymeric NPs is a slow, diffusion-controlled process that also depends on the rate of polymer biodegradation (40) . We studied release by dialyzing the Pt-encapsulated NPs against 20 L of PBS at pH 7.4 and 37°C to mimic physiological conditions. The amount of platinum released from the particles was measured by atomic absorption spectroscopy (AAS). The controlled release of platinum from the NPs is shown in Fig. 2 . An initial burst release during the first 2 h represents only 12% of the total platinum. The dormant period lasts Ϸ14 h (49%). Thereafter, a period of controlled platinum release occurs, reaching a value of 66% after 24 h. Such controlled release of Pt(IV) from the NPs extended over 60 h. These physicochemical properties confirmed our choice of the platinum(IV) compound 1, having linear hexyl chains in the axial positions, as optimal for building a sustainedrelease platinum-nanoparticle conjugate.
The identity of the platinum species released from the polymeric nanoparticles was determined by electrospray ionization mass spectrometry (ESI-MS). ESI-MS analysis of the PBS dialysate from the Pt-NP dialysis experiment revealed a peak at 553.5 (Fig. S3b) corresponding to the sodium adduct of 1 [(MϩNa ϩ ) calcd 553.34]. This result indicates that the acidic environment inside the NPs is insufficient to promote conversion of 1 to its platinum(II) form cisplatin, assuring that 1 Scheme 1. Chemical structure of the hydrophobic platinum(IV) compound 1 and the chemistry by which the active drug, cisplatin is released, after reduction in the cell.
remains in its unmodified form after entrapment in the particles, making them a valuable delivery vehicle for Pt(IV) compounds. We also investigated the redox potential for reduction of 1 at various pH values. Electrochemical analyses revealed that 1 displays an irreversible cyclic voltammetric response for the Pt(IV)/Pt(II) couple near Ϫ0.805 V vs. NHE in MeCN and approximately Ϫ0.233 V and Ϫ0.243 V vs. NHE in a 1:4 mixture of DMF-sodium phosphate buffer at pH 7.4 and 6.0, respectively (Figs. S4 -S6 ). These reduction potentials suggest that the compound should be sufficiently stable toward reduction in the bloodstream during delivery to the target cell by the nanoparticles.
Targeted Endocytosis and Endosomal Localization of Pt(IV)-Encapsu-
lated A10 PSMA Apt Functionalized NPs. Because nanoparticle uptake into cells occurs by various processes, including phagocytosis and endocytosis, we performed studies to investigate the uptake mechanism of our conjugate. Visible evidence of targeted uptake of Pt-NP-Apt by PSMA-expressing prostate cancer cells via endocytosis was obtained by f luorescence microscopy with the use of NPs containing both 1 and a green f luorescent labeled cholesterol derivative, 22-NBD-cholesterol. PSMA is highly expressed on virtually all prostate cancer cells and is currently the focus of several diagnostic and therapeutic strategies (41, 42) . LNCaP human prostate epithelial cells express a high level of PSMA protein on their cell surface and represent a good model for in vitro and in vivo prostate cancer studies. PC3 human prostate epithelial cells normally do not express any detectable levels of the PSMA protein. We examined LNCaP (PSMA ϩ ) and PC3 (PSMA Ϫ ) cells to measure the enhanced uptake of the 1-encapsulated PSMA-targeted NPs against LNCaP but not PC3 cells. As shown in Fig. 3 , incubation of LNCaP cells with the Pt(IV) and cholesterol-coencapsulated PSMA-targeted NPs for 2h and use of the early endosome marker EEA-1 antibody revealed complete internalization of the nanoparticles by receptor mediated endocytosis. In contrast, no significant accumulation of the NPs was observed in the PC3 cells, further confirming the differential binding and uptake of targeted NPs by receptor mediated endocytosis. From the release study mentioned above, we observed only 12% of total Pt(IV) to be released after 2 h in PBS at 37°C, indicating that complete internalization of the particles within 2 h is sufficient to deliver almost all their platinum(IV) content to the cells.
In Vitro Cellular Cytotoxicity Assays. We performed a series of in vitro cytotoxicity assays to evaluate the anti-cancer potential of platinum(IV)-encapsulated targeted nanoparticles, using LNCaP (PSMA ϩ ) and PC3 (PSMA Ϫ ) cells and directly comparing its efficacy to that of cisplatin. As shown in Fig. 4 A These results demonstrate aptamer-targeted delivery of a Pt(IV) prodrug to PSMA-expressing LNCaP cells by a nanoparticle delivery system. The PSMA aptamer-targeted Pt(IV)-encapsulated PLGA-b-PEG nanoparticles are 80 times more toxic than free cisplatin in the PSMA ϩ LNCaP cells, indicating the potential of these nanoparticles to treat human prostate cancer.
Visualization of Cisplatin 1,2-d(GpG) Intrastrand Adduct by Immuno-
fluorescence. The anticancer activity of cisplatin is based on the formation of intrastrand cross-links on nuclear DNA (9) . Several such adducts have been structurally identified, of which the 1,2-guanine-guanine intrastrand cross-link cis{Pt(NH 3 ) 2 d(GpG)} represents Ͼ65% of total DNA platination. We used a monoclonal antibody R-C18 specific for this adduct (43) to learn whether cisplatin released from reduction of 1 forms this cross-link with nuclear DNA. After a 12-h incubation of PSMA ϩ , LNCaP cells with Pt-NP-Apt, formation of the 1,2-d(GpG) intrastrand cross-links was observed by antibody-derived green f luorescence in the nuclei of these cells (Fig. S7) . These results confirm the complete delivery pathway of cisplatin via 1 to PSMA-expressing prostate cancer cells through targeted nanoparticle endocytosis followed by reduction of 1 to deliver a lethal dose of the drug, which forms its signature adduct on nuclear DNA in the cell.
Comparison to Related Work. While this article was in preparation, a related report appeared in which the previously described Pt (IV) compound, c,t,c- (44) . Although the system is unstable in water and stabilization required encapsulation in shells of amorphous silica, the targeted NPs with c(RGDfK) on the surface exhibited IC 50 values of 9.7-11.9 M with ␣ v ␤ 3 integrin-up-regulated HT-29 cells. These values are comparable to that of free cisplatin (13.0 M).
Summary. In this study, a hydrophobic platinum(IV) compound 1 was synthesized for encapsulation in the PLGA-b-PEG nanoparticles by the nanoprecipitation method, resulting in moderately highly loaded particles of suitable size for delivering cisplatin to prostate cancer cells. The particles were targeted to PSMA, which is overexpressed in prostate cancer, by decorating the surface of the particles with the A10 aptamer that specifically binds to the extracellular domain of PSMA. The aptamer-facilitated cellular uptake of the Pt(IV)-encapsulated nanoparticles by PSMA ϩ LNCaP cells via endocytosis was demonstrated using an antibody specific for endosome formation. The aptamer-derivatized Pt(I V)-encapsulated nanoparticles are significantly superior to cisplatin or nontargeted nanoparticles against the LNCaP cells. Cisplatin produced by reductive release from the nanoparticles forms 1,2-d(GpG) intrastrand cross-links at the nuclear DNA of the LNCaP cells. The strategy of delivering a Pt(IV) compound selectively to prostate cancer cells opens up avenues for systemic targeted therapy against this cancer using platinum drugs. More broadly, by targeting other tumorspecific antigens, using similarly engineered nanoparticles, it may be possible to selectively deliver a therapeutic dose of platinum drugs to a myriad of cancers. Further studies with relevant animal models are needed.
Materials and Methods

Potassium tetrachloroplatinate(II) was obtained as a gift from Engelhard Corporation (now BASF). Cisplatin (45) and c,c,t-[Pt(NH3)2Cl2(OH)2] (46)
were synthesized as previously described. N-hydroxysuccinimide (NHS), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), paraformaldehyde, hydroxyethyl starch (HEAS), and hexanoic anhydride were purchased from Aldrich. PLGA with acid end groups was purchased from Adsorbable Polymers International. A PEG polymer of molecular weight 3,400 with a terminal amine and carboxylic group (NH2-PEG-COOH) was custom synthesized (Nektar Therapeutics). The RNA aptamer with the sequence 5Ј-NH2-spacer GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGGCiT-3Ј containing 2Ј-fluoro pyrimidines, a 3Ј-inverted T cap, and a 5Ј-amino group attached by a hexaethyleneglycol spacer was custom synthesized by RNA-TEC. Green fluorescent dye, 22-NBD-cholesterol, was purchased from Invitrogen. Early endosomal marker, mouse monoclonal EEA-1, was obtained from Abcam. The secondary antibody for EEA-1, Cy5 goat anti-mouse antibody, was purchased from Invitrogen. For detection of the cisplatin 1,2-d(GpG) intrastrand adduct, we used a monoclonal adduct specific antibody R-C18 kindly provided by J. Thomale (University of Essen, Duisburg-Essen, Germany). FITC labeled secondary antibody rabbit anti-(rat Ig) was obtained from Invitrogen. Specific adhesion slides for immunofluorescence were purchased from Squarix Biotechnology. 1 H, 13 C, and 195 Pt NMR spectra were recorded on a Bruker AVANCE-400 spectrometer with a Spectro Spin superconducting magnet in the MIT Department of Chemistry Instrumentation Facility. ESI-MS analyses were performed on an Agilent 1100 series instrument. Atomic absorption spectroscopic measurements were taken on a PerkinElmer AAnalyst 300 spectrometer. Fluorescence imaging studies were performed with an Axiovert 200M inverted epifluorescence microscope (Zeiss) equipped with an EM-CCD digital camera C9100 (Hamamatsu). An X-Cite 120 metal-halide lamp (EXFO) was used as the light source. The microscope was operated with Volocity software (Improvision). Electrochemical measurements were performed at 25°C on a VersaSTAT3 Princeton Applied Research electrochemical analyzer with V3-Studio electrochemical analysis software, using a 3-electrode set-up comprising a glassy carbon working electrode, platinum wire auxiliary electrode, and a Ag/AgCl reference electrode. The electrochemical data were uncorrected for junction potentials. Tetra-n-butyl ammonium hexafluorophosphate and KCl were used as supporting electrolytes. To a solution of c,c, 
Synthesis of c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2CH2CH2CH3)2] (1).
Synthesis of Pt(IV)-Encapsulated NPs (Pt-NPs).
Copolymer PLGA-b-PEG containing terminal carboxylate groups was synthesized by the amide coupling of COOH-PEG-NH 2 to PLGA-COOH in methylene chloride as described in ref. 34 . Pt(IV)-encapsulated NPs were prepared by using the nanoprecipitation method. PLGA-b-PEG (10 mg/ml) and 1 at varying concentrations with respect to the polymer concentration were dissolved in acetonitrile. This mixture was slowly added to water over a period of 10 min. The NPs formed were stirred at room temperature for 3 h and then washed 3 times, using Amicon ultracentrifugation filtration membranes with a molecular mass cutoff of 100 kDa. The NP size was obtained by quasi-electric laser light scattering by using a ZetaPALS dynamic light-scattering detector (15 mW laser, incident beam ϭ 676 nm, Brookhaven Instruments). The Pt content in the NPs was measured by atomic absorption spectroscopy.
Conjugation of Apt on the Surface of Pt(IV)-Encapsulated NPs (Pt-NP-Apt).
A Pt(IV)-encapsulated PLGA-b-PEG-COOH NP suspension in DNase RNase-free water (Ϸ10 g/L) was treated with 400 mM EDC and 100 mM NHS for 15 min at room temperature with mild agitation to give the corresponding NHS-ester. The NHS-activated NPs were washed twice using Amicon ultracentrifugation filtration membrane with a molecular mass cutoff of 100 kDa to remove unreacted NHS and conjugated to 5Ј-NH 2-modified A10 PSMA Apt of 2% weight compared with polymer concentration for 2 h at room temperature with gentle stirring. The resulting Apt conjugated Pt(IV)-encapsulated NPs, Pt-NP-Apt, were washed 3 times with DNase RNase-free water using Amicon filters and resuspended in PBS.
Release of 1 from the PLGA-b-PEG NPs. A suspension of Pt(IV)-encapsulated particles in water was aliquotted (100 L) into several semipermeable minidialysis tubes (molecular mass cutoff 100 kDa; Pierce) and dialyzed against 20 L PBS (pH 7.4) at 37°C. At a predetermined time, an aliquot of the NP suspension was removed, dissolved in acetonitrile, and the platinum content was determined by AAS. 
Endocytosis of
